Peripheral T-Cell Lymphoma
Conditions
Interventions
Experimental group:Combination chemotherapy with polyethylene glycol modified liposome doxorubicin (PLD), cyclophosphamide, vincristine and prednisone
Sponsors
Cancer Hospital affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. ECOG PS Score: 0-2; 3. Pathology: Histologically confirmed initial treatment of aggressive Non-Hodgkin's lymphoma with T cells; - Includes peripheral T cell lymphoma, non-specific (PTCL NOS), vascular immunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and other aggressive T cell types (except NK/T cell lymphoma) 4. Objective measurable lesions (according to WHO standards); 5. Signed informed consent; 6. Estimated survival time >= 6 months; 7. Cardiac function: LVEF >= 50% by RNA detection, no myocardial ischemia by EKG, and no history of arrhythmia requiring drug intervention before enrollment 8. Hematopoietic function: WBC >= 4.0x10^9/L, ANC >= 2.0x10^9/L, PLT >= 100x10^9/L, Hb >= 90 g/L; 9. Liver function: total bilirubin, ALT and AST all = 50 mL /min.
Exclusion criteria
Exclusion criteria: 1. With primary or secondary central nervous system involvement; 2. Previous or concurrent heart disease, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valvular disease, cardiomyopathy, arrhythmias (including persistent atrial fibrillation, complete left bundle branch block, frequent ventricular premature onset); 3. Previous severe chronic skin diseases; 4. Previous allergic asthma or severe allergic disease; 5. Poorly controlled hypertension and diabetes; 6. Have a history of other tumors, except cured cervical cancer or basal cell carcinoma of the skin; 7. Patients infected with HIV, HCV or syphilis; 8. Pregnant or lactating women; 9. Patients who have previously received organ transplants; 10. Severe active infection; 11. Contraindications to the use of large doses of hormones, such as uncontrolled hyperglycemia, gastric ulcers or mental diseases; 12. A history of severe neurological or psychiatric disorders, including dementia or epilepsy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival; | — |
Countries
China
Contacts
Public ContactGuo Ye
Cancer Hospital affiliated to Fudan University
Outcome results
None listed